Literature DB >> 24327329

Targeting inflammation: impact on atherothrombosis.

Maria Giulia Marini1, Chiara Sonnino, Marco Previtero, Luigi M Biasucci.   

Abstract

Atherothrombosis is a worldwide epidemic accounting for an unacceptable toll of deaths and disabilities. Its pathophysiology is complex and hardly referable to a specific mechanism; however, in the last 20 years, a growing amount of evidence has demonstrated that inflammatory processes play a major role from the very beginning to the ultimate complication of atherothrombosis. These evidences are addressing a growing interest toward anti-inflammatory agents as preventive or curative treatments of atherothrombosis. At present, accumulated data are not conclusive, but strong evidence exists in favor of an anti-inflammatory positive effect for several drugs as statins or renin-angiotensin inhibitors. More conclusive data are expected from ongoing trials directly exploring the role of specific cytokines antagonists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24327329     DOI: 10.1007/s12265-013-9523-7

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  106 in total

Review 1.  By Jove! What is a clinician to make of JUPITER?

Authors:  Sanjay Kaul; Ryan P Morrissey; George A Diamond
Journal:  Arch Intern Med       Date:  2010-06-28

2.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

Review 3.  Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson
Journal:  Cardiovasc Drugs Ther       Date:  2009-01-14       Impact factor: 3.727

4.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

6.  Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability.

Authors:  L M Biasucci; G Liuzzo; R L Grillo; G Caligiuri; A G Rebuzzi; A Buffon; F Summaria; F Ginnetti; G Fadda; A Maseri
Journal:  Circulation       Date:  1999-02-23       Impact factor: 29.690

7.  Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.

Authors:  S B Larsen; E L Grove; S D Kristensen; A-M Hvas
Journal:  Thromb Haemost       Date:  2013-02-14       Impact factor: 5.249

8.  Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque.

Authors:  L Jonasson; J Holm; O Skalli; G Bondjers; G K Hansson
Journal:  Arteriosclerosis       Date:  1986 Mar-Apr

Review 9.  The role of IL-1 in the pathogenesis of heart disease.

Authors:  Marcin Bujak; Nikolaos G Frangogiannis
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-05-29       Impact factor: 4.291

10.  Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes.

Authors:  Luigi M Biasucci; Giovanna Liuzzo; Alessandra Ciervo; Andrea Petrucca; Maddalena Piro; Dominick J Angiolillo; Filippo Crea; Antonio Cassone; Attilio Maseri
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

View more
  6 in total

Review 1.  Review and Updates in Regenerative and Personalized Medicine, Preclinical Animal Models, and Clinical Care in Cardiovascular Medicine.

Authors:  Emanuele Barbato; Paul J Barton; Jozef Bartunek; Sally Huber; Borja Ibanez; Daniel P Judge; Enrique Lara-Pezzi; Craig M Stolen; Angela Taylor; Jennifer L Hall
Journal:  J Cardiovasc Transl Res       Date:  2015-10-09       Impact factor: 4.132

2.  Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra.

Authors:  Chiara Sonnino; Sanah Christopher; Claudia Oddi; Stefano Toldo; Raquel Appa Falcao; Ryan D Melchior; George H Mueller; Nayef A Abouzaki; Amit Varma; Michael L Gambill; Benjamin W Van Tassell; Charles A Dinarello; Antonio Abbate
Journal:  Mol Med       Date:  2014-11-18       Impact factor: 6.354

Review 3.  Inflammation and C-reactive protein in atrial fibrillation: cause or effect?

Authors:  Roberto Galea; Maria Teresa Cardillo; Annalisa Caroli; Maria Giulia Marini; Chiara Sonnino; Maria L Narducci; Luigi M Biasucci
Journal:  Tex Heart Inst J       Date:  2014-10-01

4.  Uric acid within the "normal" range predict 9-year cardiovascular mortality in older individuals. The InCHIANTI study.

Authors:  Gloria Brombo; Francesco Bonetti; Stefano Volpato; Mario L Morieri; Ettore Napoli; Stefania Bandinelli; Antonio Cherubini; Marcello Maggio; Jack Guralnik; Luigi Ferrucci; Giovanni Zuliani
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-06-28       Impact factor: 4.222

Review 5.  Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Authors:  Katherine Kearney; Darren Tomlinson; Kerrie Smith; Ramzi Ajjan
Journal:  Cardiovasc Diabetol       Date:  2017-03-09       Impact factor: 9.951

Review 6.  Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis.

Authors:  Ping Zhou; Weijie Xie; Shuaibing He; Yifan Sun; Xiangbao Meng; Guibo Sun; Xiaobo Sun
Journal:  Cells       Date:  2019-02-28       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.